A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis

作者：Insogna Karl L^*; Briot Karine; Imel Erik A; Kamenicky Peter; Ruppe Mary D; Portale Anthony A; Weber Thomas; Pitukcheewanont Pisit; Cheong Hae Il; de Beur Suzanne Jan; Imanishi Yasuo; Ito Nobuaki; Lachmann Robin H; Tanaka Hiroyuki; Perwad Farzana; Zhang Lin; Chen Chao Yin; Theodore Oklota Christina; Mealiffe Matt; Martin Javier San; Carpenter Thomas O

来源：Journal of Bone and Mineral Research, 2018, 33(8): 1383-1393.

DOI：10.1002/jbmr.3475

• BUROSUMAB
• FGF23
• X-LINKED HYPOPHOSPHATEMIA (XLH)
• OSTEOMALACIA
• VITAMIN D

In X-linked hypophosphatemia (XLH), inherited loss-of-function mutations in the PHEX gene cause excess circulating levels of fibroblast growth factor 23 (FGF23), leading to lifelong renal phosphate wasting and hypophosphatemia. Adults with XLH present with chronic musculoskeletal pain and stiffness, short stature, lower limb deformities, fractures, and pseudofractures due to osteomalacia, accelerated osteoarthritis, dental abscesses, and enthesopathy. Burosumab, a fully human monoclonal antibody, binds and inhibits FGF23 to correct hypophosphatemia. This report summarizes results from a double-blind, placebo-controlled, phase 3 trial of burosumab in symptomatic adults with XLH. Participants with hypophosphatemia and pain were assigned 1:1 to burosumab 1 mg/kg (n = 68) or placebo (n = 66) subcutaneously every 4 weeks (Q4W) and were comparable at baseline. Across midpoints of dosing intervals, 94.1% of burosumab-treated participants attained mean serum phosphate concentration above the lower limit of normal compared with 7.6% of those receiving placebo (p < 0.001). Burosumab significantly reduced the Western Ontario and the McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale compared with placebo (least squares [LS] mean +/- standard error [SE] difference, -8.1 +/- 3.24; p = 0.012). Reductions in WOMAC physical function subscale (-4.9 +/- 2.48; p = 0.048) and Brief Pain Inventory worst pain (-0.5 +/- 0.28; p = 0.092) did not achieve statistical significance after Hochberg multiplicity adjustment. At week 24, 43.1% (burosumab) and 7.7% (placebo) of baseline active fractures were fully healed; the odds of healed fracture in the burosumab group was 16.8-fold greater than that in the placebo group (p<0.001). Biochemical markers of bone formation and resorption increased significantly from baseline with burosumab treatment compared with placebo. The safety profile of burosumab was similar to placebo. There were no treatment-related serious adverse events or meaningful changes from baseline in serum or urine calcium, intact parathyroid hormone, or nephrocalcinosis. These data support the conclusion that burosumabis a novel therapeutic addressing an important medical need in adults with XLH.

• 出版日期2018-8